The enrichment of inflammation‐related signalling cascades—IL‐17 pathway, TNF signalling, complement activation—further emphasises the centrality of inflammatory processes in NSCLC pathogenesis and offers potential targets for therapeutic development. Here, TNF is linked to non-small cell lung carcinoma.